All episodes

Episode 123: Steven Salzberg's Twitter debate, a health tech mega-deal & Covid-19 vaccine prices

Episode 122: Gary Washburn on the NBA bubble, plus a DIY coronavirus vaccine, & behind VC numbers

Episode 121: Kate Bingham on vaccine data, Meg Tirrell on covering Covid-19, & a DNA detective story

Episode 120: Moderna's vaccine data, saving the U.S. pandemic response & systemic racism in medicine

Episode 119: Trump's FDA pressure, a microcosm of the pandemic, and squabbling over a vaccine

Episode 118: Remdesivir’s controversial cost, early vaccine promise, and AI at the end of life

Episode 117: Covid-19’s U.S. surge, GSK’s mystery whistleblower, and cancer care under coronavirus

Episode 116: Ezekiel Emanuel on vaccine politics & Tshaka Cunningham on diversifying genetic testing

Episode 115: The Chan-Zuck uprising, a virtual BIO, and the struggle to treat Covid-19

Episode 114: The killing of George Floyd, the drug industry's response, and what comes next

Episode 113: Life after a coronavirus vaccine, virtual ASCO, and remembering Larry Kramer

Episode 112: Moderna's scant coronavirus data and the plight of the day trader

Episode 111: Covid-19 in the White House, a Parkinson’s experiment & public health lessons from porn

Episode 110: Pandemic projections, Gilead's pricing dilemma & fighting Covid-19 in New York

Episode 109: Scott Gottlieb on Covid-19 treatments, reopening America, and going on TV every day

Episode 108: A vaccine official is ousted, how to use ventilators, & the fate of the JPM conference

Episode 107: Covid-19 disrupts D.C., how not to be boring on Zoom, and the trial of Elizabeth Holmes

Episode 106: Privacy in a pandemic, biopharma's big opportunity, and Shkreli's plea for a break

Episode 105: Pandemic exit strategies, how the outbreak affects patients, and Ken Burns takes on DNA

Episode 104: Fauci's star turn, the latest on coronavirus, and an under-the-radar Alzheimer's drug

Episode 103: Trump's coronavirus pivot, life inside the ICU & drug development in a pandemic

Episode 102: Voices from the coronavirus pandemic, in Italy, New York, and the high seas

Episode 101: Pharma’s response to coronavirus, Google's appetite for health data, & biotech in China

Episode 100: Wall Street's coronavirus freakout, clinical trial difficulties, and a look back

Episode 99: Genetic medicine w/ Ethan Weiss, drug industry infighting, & a microbiome review

Episode 98: Les Funtleyder on biotech investing; the Zolgensma lottery & billionaire philanthropy

Episode 97: Fake outbreak news, treating coronavirus, and biotech's Mount Rushmore

Episode 96: A chemist breaks bad, the latest on the coronavirus, and pharma’s slow Bern

Episode 95: The latest on the China virus, Sarepta's ongoing FDA saga, and biotech at Davos

Episode 94: EQRx's Alexis Borisy, Stephen Buck on his website for cancer patients, and a JPM recap

Episode 93: Josiah Zayner on getting canceled, good news in cancer, an Ebola vaccine saga

Episode 92: The decade in breakthroughs, the year in bad CEOs, and the viruses that cure disease

Episode 91: CAR-T's future, an alarming cancer trend & Chris Garabedian on Sarepta's FDA legacy

Episode 90: Biogen's big reveal, hot takes on Alzheimer's, & the science of one-eyed sheep

Episode 89: Warren's awkward home front, a dwarfism drug, and the sound of STAT Summit

Episode 88: Dr. David Sable on an alarming genetic test & Jorge Conde on the perils of bio-Twitter

Episode 87: Derek Lowe on China's new Alzheimer's drug, blockbuster fish oil, & STAT's birthday

Episode 86: Drugs that don't work, wearables in the desert, & excess 'innovation'

Episode 85: Every angle on Biogen's shocking Alzheimer's news

Episode 84: CRISPR with Netflix filmmakers, Pharma's future in China & where VC dollars come from

Episode 83: How biotech VC works w/ health care journalist Maggie Fox, Vioxx and synthetic biology

Episode 82: Drug shortages with Dr. Ben Davies, congressional paralysis & biotech's foul mood

Episode 81: Vaping upheaval, DNA test dynamics, & the future of genome editing

Episode 80: Unicorn growth spurts, Amgen's future, & mice on Twitter

Episode 79: Pelosi's drug pricing plan, Moderna's mRNA drug factories, and a DIY disease cure

Episode 78: Pharma existentialism, mainstreaming cyborgs, & FDA palace intrigue

Episode 77: Purdue, J&J, and a week of big opioid crisis news

Episode 76: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech

Episode 75: The serious side of spit kits, how BiTEs leave a mark, & Sarepta's sluggish study

Episode 74: Novartis and the no good, very bad week

Episode 73: Canadian pills, corporate jets, & racists with spit kits

Episode 72: Vertex's regime change, the return of Ebola, & the rise of digital health

Episode 71: Elon Musk's monkey cyborg, Gilead's shifting future, & an app for anxiety

Episode 70: A whirlwind week in Washington, Sean Parker's mansion, & remembering a voice in biotech

Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

Episode 68: A controversial desire drug, courtroom genealogy, & the quest for longer life

Episode 67: Biohacking meets bureaucracy, and the latest twist in CRISPR world

Episode 66: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party

Episode 65: A special episode from the halls of the ASCO meeting

Episode 64: Feuding professors, failing businesses, and journalism 101

Episode 63: Your ASCO preview, genetic whiplash, and a journalist's experience with cancer

Episode 62: Drug pricing partisanship, tech's march into health care, and Tinder for clinical trials

Episode 61: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

Episode 60: Boardroom drama, whiskey-fueled science, & millionaires on mushrooms

Episode 59: When scientists get mad online, for-profit cancer care, & the perils of naming a startup

Episode 58: Democratizing CRISPR, drugging the undruggable, and reading pharma's fine print

Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst

Episode 56: Cheaper insulin, the next Juul, and diagnosing disease with sound

Episode 55: The fate of Bristol-Myers-Celgene, the tragedy of SIDS, and health tech's challenges

Episode 54: Another big Alzheimer’s failure, postpartum progress, and Long Island shores

Episode 53: How startups stop, the new FDA boss, and Theranos on the big screen

Episode 52: Every conceivable angle of Scott Gottlieb's FDA resignation

Episode 51: CEOs at the Senate, merger mania, and sleuthing startups

Episode 50: A big scoop on opioid marketing

Episode 49: Painkiller racketeering, the limits of genetic tests, and pharma's day on the Hill

Episode 48: The AI hype machine, ketamine's future, and the rocky path ahead for NASH

Episode 47: A bad day for bold biotech, campaign 2020, and where do drugs come from?

Episode 46: Another Alzheimer's setback, crypto for biotech, and a blessing of unicorns

Episode 45: CRISPR upheaval, Celgene's chutzpah, and canine genomics

Episode 44: FDA furloughs, '80s pop radio, and video game therapeutics

Episode 43: A people's history of J.P. Morgan

Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring

Episode 41: Watson's latest stumble, a glimpse into the crystal ball, and revisiting Sarepta

Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests

Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history

Episode 38: Your guide to the #CRISPRbabies controversy

Episode 37: The biggest-ever IPO, drug prices rising in tandem, and burner Twitter accounts

Episode 36: What the midterms mean, a golden age on hold, and the $4 million drug

Episode 35: Biotech's October slump, the precise cost of precision, and breaking postpartum silence

Episode 34: Pharma at the ballot box, the latest Alzheimer's argument, and a rare disease dilemma

Episode 33: Drug prices on TV, immortal blockbusters, and genetic privacy

Episode 32: Fake friends at the FDA, cancer counter-narratives, and biotech's bear turn

Episode 31: Nobel snubs, millenial founders, and a new kind of lightning round

Episode 30: A fish oil epiphany, VC monopolies and ketamine clinics

Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem

Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping

Episode 27: Live from Boston!

Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer

Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags

Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T